Brookline Capital Management Predicts CGTX FY2025 Earnings

Cognition Therapeutics, Inc. (NASDAQ:CGTX) – Brookline Capital Management issued their FY2025 earnings estimates for shares of Cognition Therapeutics in a research report issued on Tuesday, February 3rd. Brookline Capital Management analyst F. Ahmed expects that the company will post earnings per share of ($0.35) for the year. Brookline Capital Management currently has a “Strong-Buy” rating on the stock. The consensus estimate for Cognition Therapeutics’ current full-year earnings is ($0.80) per share. Brookline Capital Management also issued estimates for Cognition Therapeutics’ Q4 2025 earnings at ($0.06) EPS, Q1 2026 earnings at ($0.07) EPS, Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.26) EPS and FY2026 earnings at ($0.46) EPS.

CGTX has been the topic of several other research reports. Wall Street Zen upgraded Cognition Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. HC Wainwright reissued a “buy” rating and issued a $3.00 target price on shares of Cognition Therapeutics in a research note on Thursday, December 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Cognition Therapeutics in a report on Monday, December 29th. Finally, B. Riley reaffirmed a “buy” rating and issued a $3.00 price target (up previously from $2.00) on shares of Cognition Therapeutics in a research report on Friday, November 21st. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $3.33.

Cognition Therapeutics Stock Performance

Shares of NASDAQ CGTX opened at $1.00 on Friday. The company has a 50 day simple moving average of $1.45 and a two-hundred day simple moving average of $1.56. Cognition Therapeutics has a fifty-two week low of $0.22 and a fifty-two week high of $3.83. The company has a market capitalization of $88.24 million, a price-to-earnings ratio of -2.08 and a beta of 1.25.

Cognition Therapeutics (NASDAQ:CGTX) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.01.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Jones Financial Companies Lllp bought a new stake in Cognition Therapeutics in the 3rd quarter worth about $25,000. Gamco Investors INC. ET AL purchased a new stake in shares of Cognition Therapeutics during the 3rd quarter valued at about $27,000. Private Management Group Inc. bought a new stake in shares of Cognition Therapeutics in the third quarter worth approximately $32,000. CWA Asset Management Group LLC purchased a new position in shares of Cognition Therapeutics during the third quarter valued at approximately $34,000. Finally, Raymond James Financial Inc. lifted its position in Cognition Therapeutics by 34.7% during the third quarter. Raymond James Financial Inc. now owns 29,641 shares of the company’s stock valued at $40,000 after purchasing an additional 7,641 shares during the period. 43.35% of the stock is owned by institutional investors.

Cognition Therapeutics News Roundup

Here are the key news stories impacting Cognition Therapeutics this week:

• Positive Sentiment: Brookline Capital Management upgraded CGTX to “Strong‑Buy” and published detailed EPS forecasts (examples: FY2026 -$0.46, FY2025 -$0.35, various quarterly EPS estimates). The firm’s less‑negative FY2026 outlook versus consensus could be read as improving expectations for future losses and helped drive positive sentiment. Brookline Estimates / MarketBeat
• Positive Sentiment: Cognition extended the duration of its Expanded Access Program (EAP) for Zervimesine (CT1812) in DLB, allowing participants additional months of treatment. The EAP extension signals ongoing clinical engagement, patient access and potential supportive real‑world data — all positives for a clinical‑stage biotechnology stock. GlobeNewswire: EAP Extension
• Positive Sentiment: Separate reports noted an analyst upgrade/coverage pickup (cited by Zacks/TickerReport), which can increase visibility and trading volume for the small‑cap name. TickerReport / Upgrade
• Neutral Sentiment: Despite the positive headlines, consensus estimates show Cognition remains expected to be loss‑making (consensus FY ~ -$0.80). Investors should weigh improved analyst outlooks and program updates against continued negative earnings and clinical‑stage execution risk.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative disorders, with an emphasis on Alzheimer’s disease. The company’s lead investigational candidate, CT1812, is an oral small molecule that antagonizes the sigma-2 receptor complex to protect synapses from amyloid-beta oligomer toxicity. By targeting a novel mechanism of action, Cognition Therapeutics aims to slow or reverse cognitive decline in patients living with Alzheimer’s disease.

CT1812 has successfully completed Phase 1 safety studies and preliminary Phase 2a trials, and is currently being evaluated in multiple Phase 2 clinical studies across North America and Europe in patients with mild-to-moderate Alzheimer’s disease.